CAS NO: | 1243262-17-0 |
包装 | 价格(元) |
1mg | 电议 |
5mg | 电议 |
生物活性 | Demcizumab (OMP 21M18) is an anti-DLL4monoclonal antibody. Demcizumab is a potent inhibitor of theNotchpathway. Demcizumab alone or in combination with chemotherapy is effective in variouscancermodels[1][2][3]. | ||||||||
IC50& Target | DLL4[1] | ||||||||
体外研究 (In Vitro) | Demcizumab (0-100 μg/mL) 结合人 DLL4 但不结合鼠 DLL4,并在 FACS 结合测定中阻断 DLL4 与 Notch1 受体的结合[3]。 Cell Viability Assay[4]
| ||||||||
体内研究 (In Vivo) | Demcizumab (10 mg/kg,i.p.,每周一次) 联合 Irinotecan (7.5 mg/kg) 在 KRASWT和 KRASMTCRC 异种移植模型中显示出显着的抗肿瘤作用[2].
| ||||||||
分子量 | 145.65 (kDa) | ||||||||
CAS 号 | 1243262-17-0 | ||||||||
储存方式 | Please store the product under the recommended conditions in the Certificate of Analysis. |